Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Eagle's Eye View: Your Weekly CV Update From ACC.org

BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement

30 Jul 2025

Description

In this week's View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve replacement (TAVR). Finally, Dr. Eagle examines long-term risk of infective endocarditis and why it is significantly higher for mitral valve (MV) replacement versus repair.    Subscribe to Eagle's Eye View  

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.